Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Juli 2020 08:00 ET | Quelle: Biond Biologics

Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual Meeting

Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first...
01. Juni 2020 08:00 ET | Quelle: Biond Biologics

Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update

Dr. Zeldis adds extensive clinical development expertise to Board BND-22, a novel immuno-oncology agent that targets the ILT2 receptor, on track for Q4 2020 IND submission MISGAV, Israel, June 01,...
25. November 2019 07:00 ET | Quelle: Biond Biologics

Biond Biologics Appoints Immunotherapy Pioneer Alan Korman Ph.D. to Scientific Advisory Board

MISGAV, Israel, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held Israeli biotech company, developing novel immunotherapies for cancer and a...